Lexaria Bioscience (LEXX) Common Equity (2010 - 2026)

Lexaria Bioscience has disclosed Common Equity across 17 years of filings, most recently posting $6.2 million for Q1 2026.

• Common Equity for Q1 2026 came in at $6.2 million, down 8.14% year-over-year; the trailing twelve-month figure through Feb 2026 was $6.2 million (down 8.14% YoY), and the FY2025 annual result was $2.6 million, down 66.02% from the prior year.
• Common Equity came in at $6.2 million for Q1 2026 at Lexaria Bioscience, up from $4.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $11.2 million in Q1 2022 to a low of $2.6 million in Q3 2025.
• The 5-year median for Common Equity is $6.1 million (2024), against an average of $6.4 million.
• Across the five-year window, Common Equity surged 185.78% in 2024 and slumped 66.02% in 2025, its largest moves.
• Lexaria Bioscience's Common Equity stood at $5.9 million in 2022, then plunged by 43.14% to $3.4 million in 2023, then jumped by 178.53% to $9.4 million in 2024, then slumped by 51.85% to $4.5 million in 2025, then jumped by 37.29% to $6.2 million in 2026.
• The last three Common Equity figures came in at $6.2 million (Q1 2026), $4.5 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.